FDA OKs expanded use of iron deficiency drug: 3 things to know

AMAG Pharmaceuticals on Monday earned expanded FDA approval for its chronic kidney disease treatment Feraheme.

Advertisement

Here are three things to know.

1. The FDA first approved Feraheme in 2009 to treat iron deficiency anemia in adults with chronic kidney disease.

2. The drug may now also be used to treat all adults with IDA who do not respond to or are intolerant to oral iron.

3. The expanded approval doubles the amount of patients who may benefit from the drug, which is administered as an injection.

More articles on supply chain:

Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know
Amazon patents wristband that monitors supply workers’ hand movements
4 latest FDA approvals

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.